There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...

With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...

Today on Living Oklahoma we were joined by Rebecca Jones.She spoke to Matt Stafford about here journey with Alzheimer's and ...

McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...

In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four ...

STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Lenvima sales are up solidly by around 10%, with Leqembi launching into its commercial phase now at 29.4 billion JPY cumulatively. Sequential performance has been solid. With a 42.5 billion JPY ...